37766966|t|Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4/NF-kappaB p65 pathway after acute myocardial infarction.
37766966|a|Background: Tanshinone IIA, derived from Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge), constitutes a significant component of this traditional Chinese medicine. Numerous studies have reported positive outcomes regarding its influence on cardiac function. However, a comprehensive comprehension of the intricate mechanisms responsible for its cardioprotective effects is still lacking. Methods: A rat model of heart failure (HF) induced by acute myocardial infarction (AMI) was established via ligation of the left anterior descending coronary artery. Rats received oral administration of tanshinone IIA (1.5 mg/kg) and captopril (10 mg/kg) for 8 weeks. Cardiac function was assessed through various evaluations. Histological changes in myocardial tissue were observed using staining techniques, including Hematoxylin and Eosin (HE), Masson, and transmission electron microscopy. Tunel staining was used to detect cell apoptosis. Serum levels of NT-pro-BNP, IL-1beta, and IL-18 were quantified using enzyme-linked immunosorbent assay (ELISA). Expression levels of TLR4, NF-kappaB p65, and pyroptosis-related proteins were determined via western blotting (WB). H9C2 cardiomyocytes underwent hypoxia-reoxygenation (H/R) to simulate ischemia-reperfusion (I/R) injury, and cell viability and apoptosis were assessed post treatment with different tanshinone IIA concentrations (0.05 mug/ml, 0.1 mug/ml). ELISA measured IL-1beta, IL-18, and LDH expression in the cell supernatant, while WB analysis evaluated TLR4, NF-kappaB p65, and pyroptosis-related protein levels. NF-kappaB p65 protein nuclear translocation was observed using laser confocal microscopy. Results: Tanshinone IIA treatment exhibited enhanced cardiac function, mitigated histological cardiac tissue damage, lowered serum levels of NT-pro-BNP, IL-1beta, and IL-18, and suppressed myocardial cell apoptosis. Moreover, tanshinone IIA downregulated the expression of TLR4, NF-kappaB p65, IL-1beta, pro-IL-1beta, NLRP3, Caspase-1, and GSDMD-N pyroptosis-related proteins in myocardial tissue. Additionally, it bolstered H/R H9C2 cardiomyocyte viability, curbed cardiomyocyte apoptosis, and reduced the levels of TLR4, NF-kappaB p65, IL-1beta, pro-IL-1beta, NLRP3, Caspase-1, and GSDMD-N pyroptosis-related proteins in H/R H9C2 cells. Furthermore, it hindered NF-kappaB p65 protein nuclear translocation. Conclusion: These findings indicate that tanshinone IIA enhances cardiac function and alleviates myocardial injury in HF rats following AMI. Moreover, tanshinone IIA demonstrates potential suppression of cardiomyocyte pyroptosis. These effects likely arise from the inhibition of the TLR4/NF-kappaB p65 signaling pathway, presenting a promising therapeutic target.
37766966	0	14	Tanshinone IIA	Chemical	MESH:C021751
37766966	38	48	pyroptosis	Disease	
37766966	57	61	TLR4	Gene	29260
37766966	90	117	acute myocardial infarction	Disease	MESH:D009203
37766966	131	145	Tanshinone IIA	Chemical	MESH:C021751
37766966	160	187	Radix Salviae Miltiorrhizae	Chemical	-
37766966	189	214	Salvia miltiorrhiza Bunge	Chemical	-
37766966	539	552	heart failure	Disease	MESH:D006333
37766966	554	556	HF	Disease	MESH:D006333
37766966	569	596	acute myocardial infarction	Disease	MESH:D009203
37766966	598	601	AMI	Disease	MESH:D009203
37766966	718	732	tanshinone IIA	Chemical	MESH:C021751
37766966	749	758	captopril	Chemical	MESH:D002216
37766966	935	956	Hematoxylin and Eosin	Chemical	-
37766966	958	960	HE	Chemical	-
37766966	1087	1095	IL-1beta	Gene	24494
37766966	1101	1106	IL-18	Gene	29197
37766966	1193	1197	TLR4	Gene	29260
37766966	1218	1228	pyroptosis	Disease	
37766966	1289	1293	H9C2	CellLine	CVCL:0286
37766966	1319	1326	hypoxia	Disease	MESH:D000860
37766966	1342	1343	H	Disease	MESH:D000848
37766966	1359	1379	ischemia-reperfusion	Disease	MESH:D015427
37766966	1381	1384	I/R	Disease	MESH:D015427
37766966	1471	1485	tanshinone IIA	Chemical	MESH:C021751
37766966	1543	1551	IL-1beta	Gene	24494
37766966	1553	1558	IL-18	Gene	29197
37766966	1632	1636	TLR4	Gene	29260
37766966	1657	1667	pyroptosis	Disease	
37766966	1791	1805	Tanshinone IIA	Chemical	MESH:C021751
37766966	1876	1897	cardiac tissue damage	Disease	MESH:D006331
37766966	1935	1943	IL-1beta	Gene	24494
37766966	1949	1954	IL-18	Gene	29197
37766966	2008	2022	tanshinone IIA	Chemical	MESH:C021751
37766966	2055	2059	TLR4	Gene	29260
37766966	2076	2084	IL-1beta	Gene	24494
37766966	2090	2098	IL-1beta	Gene	24494
37766966	2100	2105	NLRP3	Gene	287362
37766966	2107	2116	Caspase-1	Gene	25166
37766966	2130	2140	pyroptosis	Disease	
37766966	2208	2210	/R	CellLine	CVCL:RB18
37766966	2211	2215	H9C2	CellLine	CVCL:0286
37766966	2299	2303	TLR4	Gene	29260
37766966	2320	2328	IL-1beta	Gene	24494
37766966	2334	2342	IL-1beta	Gene	24494
37766966	2344	2349	NLRP3	Gene	287362
37766966	2351	2360	Caspase-1	Gene	25166
37766966	2374	2384	pyroptosis	Disease	
37766966	2409	2413	H9C2	CellLine	CVCL:0286
37766966	2532	2546	tanshinone IIA	Chemical	MESH:C021751
37766966	2588	2605	myocardial injury	Disease	MESH:D009202
37766966	2609	2611	HF	Disease	MESH:D006333
37766966	2627	2630	AMI	Disease	MESH:D009203
37766966	2642	2656	tanshinone IIA	Chemical	MESH:C021751
37766966	2709	2719	pyroptosis	Disease	
37766966	2775	2779	TLR4	Gene	29260
37766966	Negative_Correlation	MESH:D002216	MESH:D006333
37766966	Association	MESH:C021751	29260
37766966	Negative_Correlation	MESH:C021751	MESH:D009203
37766966	Negative_Correlation	MESH:C021751	25166
37766966	Negative_Correlation	MESH:C021751	29197
37766966	Negative_Correlation	MESH:C021751	MESH:D009202
37766966	Negative_Correlation	MESH:C021751	24494
37766966	Negative_Correlation	MESH:C021751	287362
37766966	Negative_Correlation	MESH:C021751	MESH:D015427
37766966	Negative_Correlation	MESH:C021751	MESH:D006331

